Pakistan Journal of Pharmaceutical Sciences
Cure8 research brief
Why This Matters
ICAM1 is implicated in immune cell adhesion and migration, processes important in UC inflammation. A new compound that modulates ICAM1 could point to a novel therapeutic approach worth further study.
Who Should Pay Attention
Researchers in IBD drug discovery, translational immunology, and clinicians following experimental therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper reports an integrative preclinical study (in-silico and animal) exploring ICAM1 as a target in ulcerative colitis and testing a plant-derived compound, alpha-cubebene, as a possible ICAM1 inhibitor.
The authors performed molecular docking, ADMET predictions, network analysis, and MD simulation to characterize ICAM1–alpha-cubebene interactions, then tested alpha-cubebene in a dextran sulfate sodium (DSS) rat model.
They report dose-dependent improvement in disease activity and histopathology with the highest alpha-cubebene dose performing better than mesalamine in their model. The study is preclinical: findings are based on computational work and a small rodent model and do not establish safety or efficacy in humans.
This is hypothesis-generating rather than practice-changing.
Keep In Mind
Preclinical study (computational + DSS rat model). Does not demonstrate human safety or efficacy; consider this hypothesis-generating only.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPakistan Journal of Pharmaceutical Sciences
PublisherFaculty of Pharmacy and Pharmaceutical Sciences, University of Karachi
AuthorsSana Rashid
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedNov 8, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Molecular Mechanisms of Danggui Shaoyao Powder in the Treatment of Ulcerative Colitis: A Network Pharmacology Approach with Experimental Validation.
The study points to specific immune pathways (especially Th17 differentiation) and molecular targets that might explain DSP’s anti-inflammatory effects in ulcerative colitis, which could guide further preclinical and...
From discovery to mechanism: novel anti-ulcerative colitis meroterpenoids act through the PI3K/IκB-α/MAPK pathway.
The study reports a newly discovered class of marine-derived meroterpenoids and identifies a lead compound that reduced inflammatory markers and improved colitis in mice, which could eventually inform new drug...
Modulating immune toxicity in ulcerative colitis using a small molecule RAB27A inhibitor
The report describes a novel small-molecule inhibitor (IMYX-3) targeting RAB27A to reduce neutrophil-mediated damage in ulcerative colitis models, which could point to a new therapeutic approach if later validated in...